Carrying the World through Crisis with Science

Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux. Mr. Bancel currently serves on the board of directors of Qiagen N.V. and Indigo. He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.

Marc Casper is Chairman, President and Chief Executive Officer of Thermo Fisher Scientific, the world leader in serving science. He leads 75,000 global colleagues to fulfill the company’s mission of enabling its customers to make the world healthier, cleaner and safer.Marc joined Thermo Electron Corporation in 2001 as President of the Life Sciences sector. He was named Senior Vice President in 2003, and in 2005 assumed responsibility for all of the company’s operating divisions. After the merger that created Thermo Fisher Scientific in 2006, he was named Executive Vice President and President of its Analytical Technologies businesses, and in 2008 he became the company’s Chief Operating Officer. Marc has been Chief Executive Officer and President since 2009 and he became Chairman in 2020.Prior to joining Thermo Fisher, Marc served as President, Chief Executive Officer and a Director of Kendro Laboratory Products. Previously, he was President-Americas for clinical diagnostics provider Dade Behring Inc. He began his career as a strategy consultant at Bain & Company and later joined Bain Capital.Marc serves on the boards of U.S. Bancorp, U.S. - China Business Council, Brigham & Women’s Hospital and Wesleyan University. He was previously a director of the Advisory Board Company and Zimmer Holdings. Marc earned an MBA with high distinction from Harvard Business School and is a graduate of Wesleyan University, where he received a bachelor’s degree in economics.

Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Prior to joining Section 32 in 2017, he served as CEO and Chairman of Foundation Medicine, a company which transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer, until he transitioned to chairman through the close of Roche’s (NASDAQ:RHHBY) acquisition of FMI in August 2018. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010.  He currently serves as a member of the Board of Directors for Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Mike brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.  Since the early days of the pandemic, Mike has also been serving as a Senior Advisor to the Rockefeller Foundation’s efforts on COVID-19 testing.  (https://www.rockefellerfoundation.org/report/a-resetting-of-americas-response-to-covid-19/)  Mike received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.